56236-82-9

Upstream product

• 74-89-5 methylamine 
• 49584-26-1 p-cyanobenzenesulfonyl chloride 
• 108-30-5 succinic acid anhydride 
• 3119-02-6 4-cyanobenzenesulfonamide 
• 74-88-4 methyl iodide 
• 80-43-3 bis(1-methyl-1-phenylethyl)peroxide 
• 623-00-7 4-bromobenzenecarbonitrile 
• 150993-53-6 4-(benzylsulfanyl)benzonitrile 
• 143-33-9 sodium cyanide 

Downstream Products

• 10252-63-8 4-methylsulfamoyl-benzoic acid 
• 101252-53-3 4-(aminomethyl)-N-methylbenzenesulfonamide 
• 63877-94-1 4-cyano-N,N-dimethylbenzenesulfonamide 
• 117795-62-7 N-[2-(3-chlorophenyl)-2,3-epoxypropyl]-4-cyano-N-methylbenzenesulfonamide 

Relevant academic research and scientific papers

Copper-catalyzed oxidative methylation of sulfonamides by dicumyl peroxide

A novel and facile copper-catalyzed methylation of sulfonamides was herein demonstrated. The practical transformation took place readily under the oxidative conditions, and N-methyl amides (23 examples) were successfully furnished in high efficiency (up to 90% yields). Dicumyl peroxide was considered to act not only as the oxidant in the system, but also methyl donor for the methylation protocol.

HETEROCYCLIC COMPOUNDS WITH AN ROR(GAMMA)T MODULATING ACTIVITY

The present invention relates to a compound that may have an ROR(gamma)t modulating activity and can thus be useful in the treatment of cancer.

FUNGICIDAL OXADIAZOLES

Disclosed are compounds of Formula I, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein R1, Z1, R2, Z2, J, s and f are as defined in the disclosure. Also disclosed are co

Copper(i)-catalyzed N-H olefination of sulfonamides for: N -sulfonyl enaminone synthesis

This communication reports copper-catalyzed N-H olefination of sulfonamides for enaminone synthesis using saturated ketones as olefin sources. With TEMPO derivatives and O2 as oxidants, this method provided an efficient way to produce various enaminones in good yields. Mechanistic studies helped figure out the stable intermediates and develop novel methodologies for the difunctionalization of saturated ketones.

ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N- oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3', R4, R4', X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.

ISOINDOLINE INHIBITORS OF ROR-GAMMA

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

NOVEL QUINAZOLINES AS 5-HT6 MODULATORS II

The present invention relates to new compounds of formula I, or salts, solvates or solvated salts thereof, wherein Q, B, R1, R2, R3, R4, m and n are defined as in claim 1, processes for their preparation and to

Novel heteroaryl substituted piperidine derivatives which are L-CPT1 inhibitors

The invention is concerned with novel substituted piperidine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.

2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS

The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in

FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF

A compound having a partial structure represented by Formula: or a salt thereof has an excellent phosphodiesterase (PDE) IV-inhibiting effect, and is useful as a prophylactic or therapeutic agent against inflammatory diseases, for example, bronchial asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, autoimmune disease, diabetes and the like.